PCT/US00/17540






FIG. IA



SUBSTITUTE SHEET (RULE 26)


3/62 **Q 9**




SUBSTITUTE SHEET (RULE 26)

M

FIG.




-1G. 4a 20.95



SUBSTITUTE SHEET (RULE 26)

FIG. 4b (2)/9




SUBSTITUTE SHEET (RULE 26)

F	il .		r .
X O			Redrow time= 10 ms
		taaagaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa	Redrow
		580 tttctootco tttctootco tttctootco tttctcootco tttctcootco tttctcootco tttctcootco tttctcootco	
		570	
		560 cotocogtt cotocogtt cotocogtt cotocogtt cotocogtt cotocogtt cotocogtt	
		550 acaggatecte cocaggatecte cocaggatecte acaggatecte acaggatecte acaggatecte acaggatecte acaggatecte	
88)		540 totectgooc	
ene (M333		530 (1000900000000000000000000000000000000	
Jence Alignment: Gene (M33388)	Colour Catculate Help	520 300000000000000000000000000000000000	
Sequence ,			
Spicene Feature Sequ	Font View	9090cGtgtc 9090cGtgtc 9090cGtgtc 9090cGtgtc 9090cGtgtc 9090cGtgtc 9090cGtgtc	
ene	Edit Font	- 257450186	
Ö	Ê	HAH HAH HAP PAP PAP PAP PAP PAP PAP PAP	done


FIG. 5

9

<u>ත</u>



SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)

0


<u>က</u>

勘 DecoGen Browser: CYP2D6	YP206							× (9) -
File Edit Help								
GENAISSANCE PHARMACEUTICAL	Population View	*						
Pathways	PID	Ethnicity	Age	Gender	HAP 1	HAP 2	Test	•
Gene Description	UP070	CA	66	F	GCCCTGGGC	GCCTGGC	0.1	
Gene Structure	UP072	2	66	Ŀ	desertesse	GCACTGGGC	0.2	
mRNA Structure	UP074	CA	66	IJ.	CCCTGGGC	GCACTGGGC	0.2	
	UP132	CA	66	×	GTGCTGGGT	GTGCTGGGT	0.3	
HAP Frequencies	UP133	క	66	M	GCGCTGGGC	GTGCTGGGT	0.2	
Population	UP134	5	66	L.	GCGCTGGGC	cccrcccc	0.1	
Linkage	UP137	ర	66	. ≥	стестесет	GTGCTGGGT	0.1	
SNP Distribution	UP009	ర	66	L	GCACTGGGC	GCACTGGGC	0.1	
Phylogenetic Tree	UP014	క	66	14.	decetecee	GCGCTGGAC	0.3	
Genotype Analysis	UP020	క	66	ij.	GTGCTGGGT	GTGCTGGGT	0.2	
Clinical Distribution	UP021	ర	66	3	ссеттетес	GCGCTGGGC	0.4	
Edit Pathway	UP022	క	66	2	GCCCTGGAC	GCGCTGGAC	0.3	
MultiGene	08001	S y	66	×	decerecee	ссеттетес	0.2	
Clinical Trial Cohorts	OR002	Ş	66	*	осостовес	GCGCTGGC	0.3	
Expression	0R004	AS	66	<u>u.</u>	GCACTGGGC	GCACTGGGC	0.2	
Assay Data	0R006	SĄ	66	<u>_</u> L_	ссепсесс	GCGCTGGAC	0.1	
References	WT003	ర	66	le.	сстсссс	ccerrerec	0.2	
	WT005	క	66	2	осстесес	осестесес	0.2	
	WT007	ర	66	æ	ссепетес	осеттетес	0.4	
	UP012	క	66	ĮL.	GCCCTAGGC	GCCCTGGAC	0.1	
	UP135	క	66	×	GCACTGGGC	GCCCTGGAC	0.2	1
0								

FIG. 9




12 / 62 <u>O</u>




BDecogen Browser: CYP206	: CYP2D6									- (∂ ×	힏
File Edit Help											
GENAISSANCE PHARMACEUTICAL Pathways	Hoplotype Frequency + - Recalculate [9]	Applotype Frequency vs. Ethnicity View	View	ا ا	·					'	
Gene Description	Details of the ethni	of the ethnic distribution as a function of subject haplotypes	tion of sub		lotypes			.		-11	4
Gene Structure mRNA Structure	3 Columns ar	Columns are given for each Ethnogeographic group: Total number sampled with HAP pair	geographic	group:							
Protein Structure	Fraction ex	Fraction of the ethnogeographic group with that HAP pair Fraction expected under Hardy-Weinberg equilibrium for that HAP pair	roup with the	hot HAP	poir or thot HAP po	÷				-	
HAP Frequencies	HAP 1	HAP 2	z	XPop.	Caucasian		African American	Hispanic/Latina	/Latino	-Se	-
Population	I ₩	*9******	23	20%			0.0%	ı	1	2	
Linkage	******L*	**************************************	C 4	4% 82	2 6.3% 18.9% 4 12.5% 2.4%		0 0.0% 2.4%	0 0.0%	0.0%	00	
SNP Distribution	*V*****O*	*********	. بی	10%	4 12.5% 25.2%		0.0%		0.0%	, -	
E	*C*****	* V***** O*	٣	29	9.4%					0	
Phylogenetic Tree	* V**** L*	********	-	2%	0.0%		12.5%			0	=
Genotype Analysis	* V * * * * L *	**************************************	0 m	4% 6%	0 0.0% 0.8%		2 25.0% 18.9% 2 25.0% 18.9%	0.00	0.0%	00	
Clinical Distribution	*V***** L*	* Y**** L*	ю	29			37.5%	0 0.0%	0.0%	0	
Edit Pathway											
MultiGene											
Clinical Trial Cohorts											
Expression											=-
Assay Data											
References					-						
											
_ 1.3										+	٠
											1

<u>N</u>




15 / 62 **<u>M</u>**




BDecogen Browser:	: CYP206					
File Edit Help						
GENAISSANCE PHARMACEUTICAL	Genotype	Recolculate View Optimized				
Pathways	Polymorphism: C	J1 ☑2 ☐ 3 ☐ 4 ☐ 5 ☐ 6	_7 ⊠8	6		Ŀ
Gene Description	Genotype Loci: L	01 52 03 04 05 06	□7 ⊡8	6		٠
Gene Structure	1(HAP): 1.	1.0 1.56 1.0 1.0 1.0 1.0	1.0 1.6 1	1.0		
	HAP 1	HAP 2	z	#Poo	Positive	
Protein Structure	*9******	*D**********			100%	
HAP Frequencies	*9*****L*	*O************************************	2 4 83	4% 8%	100% 100%	
Population	*V******	********		. %	100%	
Linkage	*C****A*	* V * * * * · · · · · · · · · · · · · ·	3 6%	22 22	100% 100%	
ribution	* V *** * L *	*D***** L*	2 42		100%	
	* V * * * * L *	* V ***** L*	2 6%		100% 100%	_
Genotype Analysis			,			
Clinical Distribution	•					
Edit Pathway						
MultiGene						
Clinical Trial Cohorts						
Expression						
Assay Data						
References						
						-
						•


 $\overline{\Omega}$


F1G.



SUBSTITUTE SHEET (RULE 26)








<u>ෆ</u>

<u>ஈ</u>



SUBSTITUTE SHEET (RULE 26)




FIG. 20

inical	Measure	ments Re	gression (Calculation		
<u>Sile</u>	Slope	Intercept	Variance	T(slope)	Significance Level	
1	-0.083	0.316	0.05	-0.59	0.7223	
2	0.154	0.231	0.04	4.22	0.9999	
3	-0.08	0.326	0.05	-1.16	0.8735	
4	-0.0080	0.313	0.06	-0.14	0.5572	
5	0.145	0.305	0.05	0.86	0.804	
6	-0.08	0.332	0.05	-1.24	0.8902	
7	0.0070	0.31	0.06	0.08	0.5303	
8	0.158	0.222	0.04	4.34	1.0	
9	-0.043	0.322	0.05	-0.76	0.7752	

FIG. 21

BDecogen Browser: CYP	r: CYP2D6	S							917	X B -
File Edit Help										
GENAISSANCE PHARMACEUTICAL	Clinical + -	Measurements vs.	Hoplotype View	Rear	Regression		1			
Pathways	Polymorp	1 13 1	6 ☐ 7 ☐ 8 ☐ 9							•
Gene Description		Summary of clir	Summary of clinical measurements vs. patient haplotypes	potient h	aplotype	ş				
Gene Structure		Measure: Test			•					
mRNA Structure		lest	,							
Protein Structure		0.0	.2[.3].4[.5].6[.7].8	9 1.0						
HAP Frequencies	I 			,						_
	⊙ Test	HAP 1	Hop 2	2	XPop.	Mean	Siddev X ** 2	X2	0(x*2 K-3)	
Linkage		*9******	*9******	23	20%	0.24	0:12	9.17	0.0	
CND Diefribution		*9****L*	*9*****	7	4%	0.15	0.07	0.0	_	
מועב הופרו ומתרומוו		*9****L*	*9****±*	4	8%	0.2	0.08	0:0	_	
Phylogenetic Tree		*V*******	*9*****	വ	10%	0.22	0.13	0.8	_	
Genetyne Analysis		*V*******	*C****A*	м ,	29	0.13	0.15	0.0	(S-)	
חביותי של ביותי שונים			*5************************************	- -	7%	0.5	0.0	0.0	_	_
Clinical Distribution		*	*****	7 "	4 0 % 8	0.55	0.07	0.0	_	
Edit Pathway		*Vessels	*V*****	o m	% % 0	.0 0.93	0.0	0.0	1.0 - - - - - - - - - - - - - - - - - - -	
MultiGene				-						
Clinical Trial Cohorts										
Expression										
Assay Data	O Test		, -							
References										
	-									
										Ξ
										J

PCT/US00/17540

	ANOVA Mod ler				_ B ×
	osurements	ANOVA (Calculation	on	
+ - Re	calculate				
Polymorphism	: 01 2 0	13 🗀 4 🗀	□ 5 □ 6 □	□7 図8 □9	
Source of Va	riation DF I	Mean Square	es F-ratio		F.
Between Grou	ips 7	0.26	19.65		_ [
Within Groups		0.01	13.03		
Critical F-Dis	tribution Value 902	Z· 1.88			-
	tribution Value 95%				ľ
	tribution Value 99%				-
Significant he	tween_arous variet	lion at the	00% ****	aa laud	ľ
	tween-group variat				1
Significant be	 WPPNハバハリカ マハガイ	tion of the	Q57 confide	ace louel	1
	tween-group variat tween-group variat				-
Significant be	tween-group variation				
					_
Significant be	tween-group variat	lion at the	99% confide	nce level	-
Significant be	tween-group variate	lion at the	99% confide Average	nce level Std. Dev.	-
Significant be	tween-group variate HAP 2 *C*****G*	ion at the	99% confide Average 0.23	Std. Dev.	-
Significant be	tween-group variate HAP 2 *C*****G* *T*****G*	N 23 2 5	99% confide Average 0.23 0.15	Std. Dev. 0.12 0.07	-
Significant be	tween-group variate HAP 2 *C*****G* *C*****A*	N 23 2	99% confide Average 0.23 0.15 0.22	Std. Dev. 0.12 0.07 0.13	
Significant be	HAP 2 *C*****G* *C*****G* *C*****G* *C********	N 23 2 5 4	99% confide Average 0.23 0.15 0.22 0.2	Std. Dev. 0.12 0.07 0.13 0.08	-
Significant be	#AP 2 *C*****G* *T*****G* *T*****G* *T******G* *T*******	23 2 5 4 2	99% confide Average 0.23 0.15 0.22 0.2 0.55	Std. Dev. 0.12 0.07 0.13 0.08 0.07	-
Significant be	#AP 2 *C*****G* *C*****G* *C*****G* *T*****G* *T******** *C******A*	23 2 5 4 2 3	99% confide Average 0.23 0.15 0.22 0.2 0.55 0.13	Std. Dev. 0.12 0.07 0.13 0.08 0.07 0.15	_
Significant bel HAP 1 *C*****G* *C*****G* *C*****A* *C*****A*	#AP 2 *C******G* *T*****G* *T******G* *T********	23 2 5 4 2 3 3	99% confide Average 0.23 0.15 0.22 0.2 0.55 0.13 0.6	Std. Dev. 0.12 0.07 0.13 0.08 0.07 0.15 0.09	_

FIG. 23






FIG. 24
SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)

28 / 62 Hap_SNP_History_ID Hap_ID Poly_ID Create_Timestamp History_Timestamp Original_Descr History_Descr GenotypeCode HapSNPHistory Genotype Descr Genotype (FK)
Hap_ID (FK)
QC
Timestamp
Descr Hap ID (FK) PI (FK) PI (FK) Poly_ID (FK) QC Timestamp Descr PattentHap PatientSNP Hap_ID Gene_ID Hap_Name Create_Timestamp History_Timestamp Original_Descr History_Descr Hap_ID (FK)
Method_ID (FK) Method ID Hap_History_ID Method Protocol Descr HapMethod HapHistory Descr FIG. 25C Poly_ID (FK) Method_ID (FK) PolySeq5 Poly_ID (FK) Poly_ID (FK) PolyMethod Seq_Text Descr Seq_Text Descr PolySeq3 Descr Gene_ID (FK) Hap_Name Timestamp Descr Hap_ID (FK) Poly_ID (FK) Timestamp Descr Haplotype AapSNP Hap_ID Feature_Key_ID (FK) Feature_Name Map_ID (FK) Descr Variation_Type (FK)
Poly_Consequence
Feature_ID (FK)
System_Name 不十 Polymorphism Gene_ID (FK) Feature_ID Length Wild Base Mut Base Poly ID Wild AA Mut AA Primer P Sample OC Descr Feature Position Hap_ID (FK) Patent_ID (FK) Pub_ID (FK) Hap_ID (FK) HapPub **HapPatent** Variation_Type Variation_Type Descr Descr Descr PolyName Alias Name Alias Ref_iD Descr Poly_ID (FK) SNPPub Pub_ID (FK) Poly_ID (FK) Descr Company_ID (FK) Poly_ID (FK)
Patent_ID (FK) Keywords Abstract MedLine_ID Publication Patent_Type Inventors Authors Institution ₽ 0 Source Patent_ID nstitution Abstract Claims Descr Descr Descr


SUBSTITUTE SHEET (RULE 26)

Patent

율




SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)

Legend of Figures:



Rectangle Boxes: Tables in the database.

Rounded Boxes: Children tables that depend on their parent tables. This dependency requires that a parent record to be in existence before a child record can be created.

- 2: Identifying parent / child relationship. It depicts the not nullable 1-to-0-or-many relationship.
- Non-identifying parent / child relationship. It represents the nullable 0-or-1-to-many relationship.
- 6: Identifying parent / child relationship. It depicts the not nullable 1-to-1-or-many relationship.
- 10: |----- Identifying parent / child relationship. It depicts the not nullable 1-to-exact-1 relationship.
- 12: Non-identifying parent / child relationship. It represents the nullable 0-or-1-to-exact-1 relationship.
- 14: $+--\Leftrightarrow$ Non-identifying parent / child relationship. It represents the not nullable 0-or-1-to-many relationship.


FIG. 25F

FIG. 26

DecoGen(TM) Browser	$\mathbf{x}[\theta]$
File Edit Subsets Action Tools Help	
Coccence of the second of the	Pothway View: Asthma
TE HAPSNP TELINkage TE Phylogenetic TE Clinical Trial Data	Extracellular OADBR2
ChinicalCorrelations Is HopEpidemiology	Intracellular
Hall Clinical Haplotype Correl	OPDE68 OIL9
6-Cluric 6-Clashmo 6-Clabetes 6-Chear Disease 6-Chalients 6-Chearis	OCALM1 OJAK3
4 Project: Aslhmo	View: Politway


SUBSTITUTE SHEET (RULE 26)

FIG. 27




SUBSTITUTE SHEET (RULE 26)

FIG. 28A




SUBSTITUTE SHEET (RULE 26)

FIG. 28B



SUBSTITUTE SHEET (RULE 26)

FIG. 291




SUBSTITUTE SHEET (RULE 26)

FIG. 29E

DecoGen(TM) Browser												F	
	ls Hefp												
	N CO CO		G-										
G Decoden	Clinical Tr	Trial Data											
TED Pothwov	182 PatientMeasurement Objects	urement O	bjects										L
Cene toble	Row Polient	זינ	Severily S	Skin Tes	FVC LP	FVC %P	FEVI L	FEV1 %	7 FEV1/FV	钽	PRE FEF	7. 2.	عٍإ
-E Ceneinfo	1SL-A4131			1.0	1.88	58.0	1.28	52.0	68.0	0.83	49.0	Γ	1.81△
- GeneStructure	2 SL-A4134			0.1	2.01	54.0	96.0	34.0	48.0	0.45	12.0	Π	2.2
Potient toble	3 SL-A4136			0.0	2.56	89.0	2.22	93.0	87.0	3.2	91.0		15.
HE HAP lyping	4 StA4150			0	1.4	50.0	9.0	27.0	43.0	0.22	7.0		1.5
LANGEND	5 SL-M15	2.0			1.77	40.0	0.98	27.0	55.0	0.61	16.0		2.2
The Day of	6 SL -A4159	T	1	Ì	2.89	0.99	1.7	51.0	59.0	6.0	20.0		4.4
The Phylogenetic	/ SL-A4195	1			4.28	96.0	2.7	79.0	63.0	1.48	33.0		5.2
Time Clinical Trol Data	8 SL M211			0	3.44	91.0	1.97	0.99	57.0	1.39	32.0		5.5
-(E-Cinicalvariables	9 SL - AA22/				1.93	24.0	96.0	37.0	49.0	0.35	11.0		<u></u>
	10 St - AA253	2			3.0	96.0	2.01	70.0	57.0	0.99	25.0	Γ	80
Hap Endemiology	11 SL -AA270				S	ď	ďΝ	dΝ	dΝ	dN	<u>₹</u>		皇
Happophylogeny	12 SL - AA275				ΝĐ	dΝ	Νb	ΔN	₹	g	<u>₽</u>	Γ	9
ElClinical Hoplotype Correl	13 SL-CA101			0.	2.17	85.0	1.92	64.0	71.0	1.33	38.0		7
	14 SL-CA103				3.56	59.0	2.16	46.0	61.0	1.13	18.0	Γ	12:
[라스 Projects	15 SL-CA104	2.2			2.76	57.0	1.46	39.0	53.0	0.59	16.0		E
P-O LURIC	16 SL-CA105				1.99	62.0	11.11	46.0	57.0	0.55	24.0	2	<u></u>
P-C Asthmo	17 SL-CA106				3.46	82.0	5.69	83.0	57.0	2.28	51.0	Γ	4.4
To Diobetes	18 SL-CA107				3.82	113.0	2.59	83.0	78.0	1.7	46.0	Γ	ō
ט ע	19 St - CA108				اچ	₽ P	ďΝ	dN .	dΝ	ΝP	dΝ		ġ.
	20 SL -CA109	2			2.63	93.0	1.7	7.0	64.5	0.89	25.0	Г	<u></u>
man repository	21SL-CA110				4.56	14.0	3.18	101.0	70.0	2.24	51.0	Г	4.5
	22 52 - (A111	7.0	7		3.08	0.69	2.01	58.0	65.0	1.12	32.0		3.3
	23 St - CA114		9	1	2.83	84.0	2.18	77.0	77.0	1.77	43.0		3.0
	24 SL-CA116	Ī	7		2.44	83.0	1.91	79.0	78.0	8.	49.0		2.4
	25 SL-CA117		†		5.81	90.0	2.25	67.0	29.0	- 9.0	22.0		4.1
	26 St - CA118		+		1.53	76.0	1.27	71.0	83.0	1.27	49.0	1	نق
	2/ SL-CA119	⋛	ੇ		d.	d.	9	ď	<u>₽</u>	₽	ď		g.
	28 51 - 141 20	3	2		4.24	090	2.71	83.0	64.0	1.61	33.0		4.4
	29 St - CA121		S)			88.0	1.9	70.0	62.0	0.95	26.0		3.6
	30 SL-CA122		2		5.76	105.0	4.35	103.0	75.5	3.52	62.0		0
	31SL-CA123	20	2		1.82	0.99	0.92	40.0	20.0	0.41	12.0		2.5
	32 SL-CA124	7.0	0.0		2.45	29.0	1.3	43.0	53.0	0.41	11.0	Г	2.5
	33 SL-CA125	2				42.0	0.81	37.0	68.0	0.47	22.0		77
•	34 StCA126	7.0 7.0	<u>8</u>	٦		64.0	1.17	52.0	67.0	0.55	18.0		
	4 SICA127	를	9		297	68.7	191	73.0	830	1 49	<u>166 6</u>	П	है। बि
Project: Asthma		\$	T. Clinica	Ver: Cinical Tool Date				Acting Cons. ADDRO	. Anona				7
								אכווגם חבוום	אטעסל:				7
	•	£.	٠.										

FIG. **30**



-1G




FIG. 32






FIG. 33



SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)

WO 01/01218

PCT/US00/17540

43/62

FIG. 35




FIG. 36





FIG. 37



SUBSTITUTE SHEET (RULE 26)




FIG. 38

DecoGen Single Ge	ene Statistics	Calculato	or				-10)×
File	 							
Show/Hide	CC Line							
Gene: adrenergic,	beto-2-,	receptor,	surface	Clinic	cal Meas	ure: Deito %	FEV1 pre	d.
			Confidence:	0.05 0.1	Fixed Si	te:4]
Regression Res								٥
Marker	Intercept	Slope	Slope Rar	nge	R** 2	Corr. Coef (R)	P-vatue	$\Box\Box$
*G*******	10.501	1.99	-0.08	4.06	0.0301	0.1734	0.0297	
	10.526	1.956	-0.11	4.02	0.0293	0.1711	0.0314	
□****** A+G+*	14.583	-2.206	-4.28	-0.13	0.0365	-0.1911	0.0187	
+A++++A+++	14.471	-2.048	-4.13	0.032	0.0315	-0.1774	0.0268	:
□**A*****G**	14.626	-2.241	-4.32	-0.16	0.0374	-0.1934	0.0175	
□**A****A*G**	14.615	-2.308	-4.4	-0.21	0.0391	-0.1977	0.0156	-
□GCACCTTTACGCC	14.6	-2.343	-4 .46	-0.22	0.0394	-0.1984	0.0153	
1				•				
	•							
İ								
								. []
1								
								Ш
							•	
								H
4								

FIG. 39A





FIG. 39B


FIG. 40



DecoGen Single Ger	ne Statistics Calculat	or					
File							
Clinical Measureme	ents ANOVA Calcula	ation					
Source of Variation	DF Mean Squares	F-rotio	-				
Between Groups	6 145.83	2.49		. H			
Within Groups	101 58.59		_	[]			
P-value for significance	e <u>:</u> 0.027	-	,	. []			
HAP List for	r ADRB2						
Choose SNPs:							
7 6 6 4	8 8 8 8 8 8 8 8 8	Ç	* •				
4 6 6 6	\$ \$ \$ \$ \$ \$ \$ \$ \$	Á					
9 8 8 8	20000000000000000000000000000000000000	Č					
20000000000000000000000000000000000000		(C) 40 40					
HAP1 HAP2	CCITIACGC	·	Std. Dev.				
1 1	24	15.21	7.38				
1 2	2	15.0	0.0				
1 3	37	11.43	8.52	11			
1 4	21	12.57		! !			
3 3 3 4	14 8	8.5 19.25	7.15	1 1			
3 5	2	19.25	9.59 7.78				
ها ا							
<u> </u>							


FIG. 41

FIG. 42




SUBSTITUTE SHEET (RULE 26)


FIG. 43




SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)

56 / 62



SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)

Legend of Figures:



Rectangle Boxes: Tables in the database.

Rounded Boxes: Children tables that depend on their parent tables. This dependency requires that a parent record to be in existence before a child record can be created.

- 2: | Identifying parent / child relationship. It depicts the not nullable 1-to-0-or-many relationship.
- 4: Non-identifying parent / child relationship. It represents the nullable 0-or-1-to-many relationship.

- 10: | Identifying parent / child relationship. It depicts the not nullable 1-to-exact-1 relationship.
- 12: Non-identifying parent / child relationship. It represents the nullable 0-or-1-to-exact-1 relationship.
- 14: |--- Non-identifying parent / child relationship. It represents the not nullable 0-or-1-to-many relationship.

FIG. 44F

PCT/US00/17540




FIG. 45
SUBSTITUTE SHEET (RULE 26)

 A_{ij}

60/62





FIG. 46

SUBSTITUTE SHEET (RULE 26)






FIG. 48




FIG. 49